Skip to main content
Signal8

GILEAD SCIENCES, INC. (GILD) Form 10-Q — Oct 29, 2026

$GILDForm 10-QFiled Oct 29, 2026, 8:09 PM ET0000882095-26-000039Original filing

Gilead's Q3 2026 revenue rose 7% to $8.3 billion, led by HIV sales up 18% (Biktarvy $4.06B, Descovy +49%, new launch Yeztugo at $305M) and Trodelvy up 42%, while Veklury collapsed 69% and Cell Therapy fell 18% on competitive headwinds. The nine-month bottom line swung to a $6.0 billion net loss (diluted EPS -$4.87) versus $6.3 billion net income a year ago, driven by roughly $11.3 billion of acquired IPR&D charges from the Arcellx ($6.4B), Tubulis ($3.2B) and Ouro Medicines ($1.9B) acquisitions plus a $1.75B IPR&D impairment — an aggressive pipeline rebuild paid for partly with $3.0B of new notes.

Key figures

Eps
1.94
Revenue
8300000000
Net Income
2429000000
Total Debt
26231000000
Revenue Yoy
7%
Total Assets
51408000000
Cash Position
6437000000
Shares Outstanding
1240338614
Yeztugo q3
305000000
Biktarvy q3
4059000000
Descovy q3 yoy
+49%
Veklury q3 yoy
-69%
Trodelvy q3 yoy
+42%
Hiv sales q3 yoy
+18%
Q3 product sales
8289000000
Q3 net income yoy
-20%
Buyback nine month
1144000000
Nine month revenue
23063000000
Arcellx acquisition
6400000000
Cell therapy q3 yoy
-18%
Tubulis acquisition
3200000000
Nine month revenue yoy
7%
Product gross margin q3
81.0%
Acquired iprnd nine month
11307000000
Pepstar agreement upfront
1275000000
Q3 diluted eps prior year
2.43
Ouro medicines acquisition
1900000000
Iprnd impairment nine month
1750000000
Dividend per share quarterly
0.82
Operating cash flow nine month
11152000000

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.